In the last 2 decades, considerable progress has been made in identifying the molecular genetic basis of several progeroid syndromes, including Werner syndrome \[[@CIT0001]\], Hutchinson-Gilford progeria syndrome \[[@CIT0002]\], atypical progeroid syndrome \[[@CIT0003]\], mandibuloacral dysplasia \[[@CIT0004], [@CIT0005]\], mandibular hypoplasia, deafness, and progeroid syndrome \[[@CIT0006]\], and more recently, neonatal progeroid syndrome \[[@CIT0007]\]. These discoveries have revealed the importance of several pathways in aging, such as those involved in the maintenance of nuclear membrane integrity by nuclear lamins A and C and in genomic stability by RECQ helicase enzymes and deoxyribonucleic acid/ribonucleic acid (DNA/RNA) polymerases, such as DNA polymerase delta 1 catalytic subunit and RNA polymerase III subunit A. Despite this progress, the molecular basis of some patients with extremely rare progeroid syndromes remains obscure. Here we report the homozygous missense variant in *PRRT3* as the molecular genetic basis of a novel autosomal recessive progeroid syndrome.

Participants and Methods {#s1}
========================

We ascertained 2 affected siblings belonging to a consanguineous Arab pedigree. This study was reviewed and approved by the Institutional Review Board of UT Southwestern Medical Center, Dallas, Texas. Both the affected participants, their parents, and unaffected siblings provided written informed consent for participation in the current study.

Clinical features of the 2 affected participants were as follows:

Patient J100.3 {#s2}
--------------

This 24-year-old male had poor weight gain, short stature, and muscle weakness since the age of 6 years. He developed puberty at age 17 years but had a high-pitched voice. His height was 156 cm (2.2 percentile, z score --2.0 using data for adult males in Jordan). At age 21 years, his body weight was 31.5 kg (z score --8.5), body mass index (BMI) was 12.9 kg/m^2^ (z score --9.5) and occipitofrontal circumference was 51.5 cm (z score --2.4), denoting microcephaly. He had micrognathia, beaked nose, small mouth, loss of lateral eyebrows, and a high-arched palate ([Fig. 1A](#F1){ref-type="fig"}, [B](#F1){ref-type="fig"}, [E](#F1){ref-type="fig"}). He had sloping shoulders, thin extremities, reduced muscle bulk, and scanty subcutaneous fat. He had severe gingivitis and myopia. He was Tanner stage IV but had no facial hair and scant axillary and pubic hair. He had some limitation of movement of full extension of the elbows, knees, and hips. He also had a short right index finger and incurved third toes ([Fig. 1F](#F1){ref-type="fig"}, [G](#F1){ref-type="fig"}).

![Clinical features of patient 1 (J100.3) with short stature, mandibular hypoplasia, osteoporosis, and short eyebrows, indicating progeroid syndrome. Anterior (**A**), and left lateral (**B**) views of the patient 1 (at age 18 years) showing thin limbs with a paucity of subcutaneous (sc) fat on the trunk and extremities and with normal hair on the scalp but lack of facial and body hair. (**C**) Anterior view of the face of patient 2 (J100.5) showing small mandible, beaked nose, and loss of lateral third of the eyebrows. (**D**) Posterior view of patient 2 showing thin limbs with paucity of sc fat on the extremities. (**E**) Anterior view of the face of patient 1 showing small mandible, beaked nose, and loss of lateral third of the eyebrows and lack of facial hair on the upper lip, chin, and cheeks. (**F**) Dorsal view of the right hand of patient 1 showing short index finger. (**G**) Dorsal view of the right foot of patient 1 showing incurved third toe. (**H**) Sagittal magnetic resonance imaging (MRI) of the head and neck through midline of patient 1 shows normal amount of sc fat in the scalp, neck, and upper chest. (**I**) Axial MRI of the chest at the level of the base of the heart of patient 1 showing normal sc fat anteriorly and posteriorly. (**J**) Axial MRI of the mid thigh of patient 1 showing normal amount of sc and intermuscular fat. (**K**) Axial MRI of the abdomen at the level of the kidneys of patient 1 showing normal amount of fat in the sc, intraperitoneal, and retroperitoneal (perinephric) region. (**L**) Audiometry of patient 1 showing moderate high frequency (8000 Hz) hearing loss in both the ears. Hearing level below 20 dB at a frequency is considered hearing loss.](bvaa088f0001){#F1}

His fasting and 2-hour postprandial blood glucose values were normal (93 mg/dL; normal range: 65-99 mg/dL, and 112 mg/dL, respectively; normal range: 65-139 mg/dL). He had normal serum total cholesterol (149 mg/dL; normal range: \<200 mg/dL), triglycerides (39 mg/dL; normal range: \< 150 mg/dL), and high-density lipoprotein (HDL) cholesterol (45 mg/dL; normal range: \> 40 mg/dL). His serum calcium (9.5 mg/dL; normal range: 8.4-10.2 mg/dL), phosphorus (3.75 mg/dL; normal range: 2.7-4.5 mg/dL); magnesium (2.11 mg/dL; normal range: 1.7-2.56 mg/dL); and alkaline phosphatase (40.7 IU/L; normal range: 40-129 IU/L) were normal. His serum parathyroid hormone was elevated (111.5 pg/mL; normal range: 9-55 pg/mL) and 25-hydroxy vitamin D level was low (12.3 ng/mL; normal range: 30-70 ng/mL). He had normal serum adrenocorticotrophic hormone (ACTH: 28.1 pg/mL; normal range: 7.2-63 pg/mL), cortisol (15.7 µg/dL; normal range: 3.7-19.4 µg/dL), thyroid-stimulating hormone (TSH: 2.12 µIU/mL; normal range: 0.35-5.01 µIU/mL), free thyroxine (9.87 pmol/L; normal range: 9.10-23.80 pmol/L), luteinizing hormone (LH: 3.25 mIU/mL; normal range: 1.14-8.75 mIU/mL), follicle-stimulating hormone (FSH: 3.68 mIU/mL; normal range: 0.95-11.95 mIU/mL), and testosterone (3.22 ng/mL; normal range: 2.41-8.27 ng/mL) concentrations. His serum growth hormone (GH) was 1.35 ng/mL (normal values: 0.4-2.47 ng/mL) but insulin-like growth factor-1 (IGF-1) concentrations repeated twice were 73.6 and 76.5 ng/mL (--3.33 standard deviation \[SD\]; normal range: 99-655 ng/mL), which were extremely low. A 240-minute 1-mg intramuscular glucagon (GlucaGen, Novo Nordisk) stimulation test at age 24 years revealed peak stimulated serum GH concentration of 3.23 ng/mL at 120 minutes from the baseline value of 0.51 ng/mL.

Roentgenograms of the wrist revealed bone age corresponding to the chronological age of 20 years. A dual-energy x-ray absorptiometry (Hologic Discovery A; Hologic, Inc., Waltham, MA) revealed an overall bone density z score of --4.78 (height-adjusted z score according to Zemel et al \[[@CIT0008]\], --2.6), lumbar 1 to 4 vertebral z score of --4.6 (height-adjusted, --2.8), and left femoral neck z score of --4.5 (height-adjusted, --3.4). There was no history of bone fractures. His total body fat was 24.4%, with arm fat of 21.4%, leg fat of 27.6%, and truncal fat of 22.9%. A whole-body magnetic resonance imaging (MRI) revealed near normal body fat distribution ([Fig. 1H-K](#F1){ref-type="fig"}). Echocardiography showed trace mitral valve regurgitation. Audiometry showed moderate bilateral high frequency (8000 Hz) sensorineural hearing loss ([Fig. 1L](#F1){ref-type="fig"}).

He died recently due to suspected food poisoning after presenting to the local hospital with vomiting and dehydration. The clinical or laboratory data for this admission are not available.

His parents were first cousins ([Fig. 2A](#F2){ref-type="fig"}). The midparental height was 172 cm. One of his younger sisters was similarly affected, and he had 4 younger healthy sisters and 1 healthy brother, all of whom were of average height and weight ([Fig. 2A](#F2){ref-type="fig"}).

![J100 pedigree and the pathogenic variant in proline-rich transmembrane protein 3 (PRRT3). (**A**) J100 pedigree. The circles denote females and squares denote males. Participants with homozygous c.1180G\>A *PRRT3* variant are shown as A/A and heterozygotes as G/A under the symbols. Symbols filled with black color indicate affected participants with progeroid syndrome, and unfilled symbols indicate unaffected participants. A slanted arrow indicates the proband, and asterisks indicate participants who underwent whole exome sequencing. Double horizontal line indicates consanguinity among parents (first cousins). Data are also included for height, weight, body mass index (BMI) and occipitofrontal circumference (OFC) for each participant. For the children and proband (assuming his age to be 19.9 years), z scores were calculated from the Centers for Disease Control (CDC) data (<https://www.cdc.gov/growthcharts/percentile_data_files.htm>.). For the adults, z score for height was calculated from <https://tall.life/height-percentile-calculator-age-country/>. (**B**) Region of homozygosity on chromosome 3 spanning approximately 15.7 Mb (9 896 351--25 632 113 bp), shared by the 2 affected individuals (J100.3 and J100.5) but not by the 2 unaffected individuals (J100.4 and J100.8). The top line represents the markers with alternate homozygous genotypes; the bottom line corresponds to the heterozygous genotypes. The rectangles highlight the homozygous regions: red if the regions are shared by more than 1 participant, gray if the regions are private to 1 participant. (**C**) The human *PRRT3* gene contains 4 exons and 3 introns. The hatched boxes indicate untranslated regions. The arrow indicates the direction of the coding transcript. The variant g.9989677C\>T; c.1180G\>A is present in exon 4 of the *PRRT3*. (**D**) Sequence electropherogram from Sanger sequencing of *PRRT3* showing wild-type sequence. (**E**) Heterozygous c.1180G\>A (p.Glu394Lys) *PRRT3* variant in an unaffected participant. (**F**) Homozygous c.1180G\>A (p.Glu394Lys) *PRRT3* variant in an affected participant.](bvaa088f0002){#F2}

Patient J100.5 {#s3}
--------------

This 18-year-old female had developmental dysplasia of the hips requiring surgery at 7 and 12 months of age. At the age of 5 years, poor weight gain, short stature, and muscle weakness were noted. She achieved menarche at 12 years of age and had irregular menstrual cycles. She had a high-pitched voice. Her height was 149 cm (1.2 percentile; z score --2.3), weight was 29.5 kg (z score --3.8) with a BMI of 13.3 kg/m^2^ (z score --5.0), and occipitofrontal circumference was 50.5 cm (z score --3.6), denoting microcephaly. She had micrognathia, beaked nose, small mouth, loss of lateral eyebrows, and a high-arched palate ([Fig. 1C](#F1){ref-type="fig"}, [D](#F1){ref-type="fig"}). She had thin and slender extremities, reduced muscle bulk, and scanty subcutaneous fat. Her breast and pubic hair development were Tanner stage III, but she had scant axillary hair.

Her fasting blood glucose was 94 mg/dL and 2-hour postprandial blood glucose was 89 mg/dL. She had normal serum total cholesterol (163 mg/dL), triglycerides (48 mg/dL), HDL cholesterol (60 mg/dL; normal range: \> 46 mg/dL), serum calcium (9.3 mg/dL), phosphorus (3.9 mg/dL), magnesium (1.99 mg/dL), alkaline phosphatase (40.6 IU/L), TSH (1.62 µIU/mL), free thyroxine (9.52 pmol/L), ACTH (24.5 pg/mL), cortisol (18.5 µg/dL), LH (3.36 mIU/mL; normal range: 1.6-12.4 mIU/mL), FSH (3.3 mIU/mL; normal range mid-follicular phase: 2.5-10.2 mIU/mL), and estradiol levels (113.4 pg/mL; normal range mid-follicular phase: 27-123 pg/mL). Her serum parathyroid hormone level was high (81.7 pg/mL) and 25-hydroxy vitamin D level was low (8.5 ng/mL). Her serum GH level was 1.96 ng/mL (normal values 1-8 ng/mL), but IGF-1 levels repeated twice were 46.6 and 46.7 ng/mL (--3.51 SD; normal range: 73-522 ng/mL), which were extremely low. A 240-minute 1-mg intramuscular glucagon (GlucaGen, Novo Nordisk) stimulation test at age 18 years revealed a peak stimulated serum GH level of 3.83 ng/mL at 120 minutes from the baseline level of 1.37 ng/mL.

She had normal hearing on audiometry and normal echocardiogram. Her bone age corresponded to the chronological age of 16 years. A dual-energy x-ray absorptiometry revealed an overall bone density z score of --3.2 (height-adjusted, --2.25), lumbar 1 to 4 vertebral z score of --2.3 (height-adjusted, --1.5), and left femoral neck z score of --3.4 (height-adjusted, --2.9). There was no history of bone fractures. Her total body fat was 32.7%, with arm fat of 32.6%, leg fat of 43%, and truncal fat of 26.6%. Her whole-body MRI revealed near normal subcutaneous and intra-abdominal fat. Follow-up at age 18 years revealed that she had developed a seizure disorder, which was controlled by medications.

Methods {#s4}
=======

Genotyping {#s5}
----------

Genomic DNA was isolated from peripheral blood using the Easy-DNA kit (Invitrogen, Carlsbad, CA). Two affected (J100.3 and J100.5) and 2 unaffected (J100.4, J100.8) siblings ([Fig. 2A](#F2){ref-type="fig"}) underwent whole exome sequencing using the SureSelect Human All Exon V4 kit on the Illumina platform. Sequencing read length was paired-end 2x100 bp. Sequences were aligned to the human reference genome b37. The mean coverage of the targeted regions for J100.3, J100.4, J100.5, and J100.8 were 99-, 95-, 126-, and 88-fold, respectively, with \>98% bases covered by \>10-fold reads in all samples. Genetic variations were called using the Genome Analysis Toolkit \[[@CIT0009]\] and annotated using SnpEff \[[@CIT0010]\]. Because of parental consanguinity and 2 of the 7 siblings being affected, we hypothesized a homozygous variant was most likely. Thus, we mapped the disease gene by a combination of 2 approaches. First, we searched for runs of homozygosity (ROH) greater than 1 Mb and shared by the 2 affected but not by the 2 unaffected siblings using BCFtools/ROH \[[@CIT0011]\]. Second, we filtered for rare missense, nonsense, splicing, or frameshift homozygous variants shared by the 2 affected but not by the 2 unaffected with minor allele frequency less than 0.01 in the 1000 Genomes Project (<http://www.internationalgenome.org/>), genome aggregation database (gnomAD v2.1.1; <http://gnomad.broadinstitute.org/>), and the Greater Middle East Variome Project database (<http://igm.ucsd.edu/gme/>). Variants with a genomic evolutionary rate profiling++ score \[[@CIT0012]\] greater than 1.0 and a combined annotation-dependent depletion score \[[@CIT0013]\] greater than 10 were considered. We considered missense variants predicted to be "probably damaging" by Polymorphism Phenotyping v2 (PolyPhen2, HumDiv; <http://genetics.bwh.harvard.edu/pph2/>). We also performed Sanger sequencing to confirm segregation of the candidate variants within the pedigree.

Messenger RNA Expression Studies {#s6}
--------------------------------

In order to study the tissue expression of *PRRT3* messenger RNA (mRNA), we designed primers in both the 5ʹ and 3ʹ regions of the gene specific to PRRT3. The human normal complementary DNA tissue array was obtained from Origene (TissueScan, Rockville, MD).

Results {#s7}
=======

The ROH analysis revealed a total of 22.1 Mb stretches of homozygous segments consisting of 5 regions greater than 1 Mb in length, which were shared by the 2 affected siblings but not by the 2 unaffected siblings. Out of the 5 regions, there was 1 significant ROH on chromosome 3 spanning approximately 15.7 Mb (9 896 351--25 632 113) ([Fig. 2B](#F2){ref-type="fig"}). There was no indication of copy number variation in the region according to ExomeDepth \[[@CIT0014]\]. There were only 2 candidate variants with minor allele frequency \< 0.01 in the ROH: the *PRRT3* variant on chromosome 3 ([Fig. 2C](#F2){ref-type="fig"}) and a *GPR110* variant on chromosome 6. The *GPR110* variant had a low PolyPhen score of 0.618, which failed the PolyPhen criterion, and furthermore, upon Sanger sequencing of all the family members, it did not segregate with the phenotype in our family. The unaffected mother was homozygous for the *GPR110* variant. The *PRRT3* homozygous variant, NC_000003.11:g.9989677C\>T leading to a c.1180G\>A nucleotide change and corresponding protein change, NP_997234.4: p.Glu394Lys, passed the filtering criteria ([Fig. 2D-F](#F2){ref-type="fig"}). This variant (rs909458664) was not seen in gnomAD or Greater Middle East Variome Project database; however, there were 3 heterozygotes among 62 784 individuals in the TOPMed database freeze5 (<https://bravo.sph.umich.edu/freeze5/hg38/>). Sanger sequencing further confirmed the segregation of this variant in the family ([Fig. 2A](#F2){ref-type="fig"}). No pathogenic variants were found in either of the affected participants in progeria or progeroid syndrome genes such as *LMNA, ZMPSTE24, BANF1, RECQL2, RECQL4, BLM, POLD1, POLR3A, WRN, ERCC4, ERCC6, ERCC8, TERT1, TERC, DKC1, AKT1P, SPRTN, XPA, XPB, XPC,* and *XPG* \[[@CIT0015]\].

PRRT3 belongs to the family of proline-rich proteins containing several repeats of a short proline-rich sequence. PRRT3 has close homology with PRRT1, PRRT2, and PRRT4, which are much smaller proteins ([Fig. 3A](#F3){ref-type="fig"}). However, the precise molecular function of PRRT3 remains to be determined. The central region of all PRRT proteins seems to be highly conserved, which may suggest similar functions of these proteins. Recently, variants in *PRRT2* have been reported to cause episodic kinesigenic dyskinesia-1 \[[@CIT0016]\]. The glutamic acid at position 394 of PRRT3 is highly conserved across species ([Fig. 3B](#F3){ref-type="fig"}).

![Alignment of various proline-rich transmembrane proteins (PRRT), conservation of the mutated glutamic acid across species, tissue expression of *PRRT3* messenger ribonucleic acid (mRNA), and schematic of the predicted human PRRT3 isoforms insertion in the cell membrane. (**A**) Snapshot of the protein alignment of PRRT 1 to 4 using National Center for Biotechnology Information constraint-based multiple alignment tool (NCBI COBALT). The highly conserved regions for these isoforms are shown in red. The conserved region spans between amino acids 216 to 461 of PRRT3. The primers used for reverse transcriptase--quantitative polymerase chain reaction (RT-qPCR) were designed in the 5ʹ and 3ʹ region of the gene so that they specifically amplify PRRT3. The amplified product using these primer sets was confirmed by Sanger sequencing. GenBank Acc\#; PRRT1 - [NM_030651.3](NM_030651.3) → [NP_085154.3](NP_085154.3); PRRT2 -- [NM_145239.2](NM_145239.2) → [NP_660282.2](NP_660282.2); PRRT3 -- [NM_207351.4](NM_207351.4) → [NP_997234.3](NP_997234.3); PRRT4 -- [NM_001114726.2](NM_001114726.2) → [NP_001108198.2](NP_001108198.2). (**B**) Alignment of partial PRRT3 amino acid sequences from the human (*H. sapiens*; [NP_997234.3](NP_997234.3)), chimpanzee (*P. troglodytes*; [XP_001149591.1](XP_001149591.1)), rhesus monkey (*M. mulatta*; [XP_001091855.1](XP_001091855.1)), gray wolf (*C. lupus*, [XP_005632236.1](XP_005632236.1)), cow (*B. taurus*; [XP_005222668.1](XP_005222668.1)), mouse (*M. musculus*; [NP_766075.2](NP_766075.2)), and rat (*R. norvegicus*; [XP_003749857.1](XP_003749857.1)). The mutated residue glutamicacid (**E**) at position 394 (shown in red in bold font) is conserved among all the species. (**C**) Expression of human *PRRT3* mRNA in various tissues. Shown are the tissues whose C~t~ values were below 30 for both 5ʹ and 3ʹ region primer sets. The relative expression of each tissue is compared with that of tonsil. Expression in the pituitary is 5- to 13-fold higher than that in the tonsil. (**D and E**) Schematic for the human PRRT3 isoform insertion in the plasma membrane based on secondary structure prediction. *PRRT3* encodes a 981 amino acid protein (long form) and a 421 amino acid protein (short form). Both the isoforms share 390 amino-terminal amino acids. The long form has 591 unique carboxy-terminal amino acids, and the short form has 31 unique carboxy-terminal amino acids. The modeling was performed using secondary structure prediction for human PRRT3 protein and a recent biochemical approach used for PRRT2 protein membrane insertion \[[@CIT0035]\]. The variant p.E394K (shown with a red X) resides in the intracellular part of PRRT3 and does not affect the short form.](bvaa088f0003){#F3}

RNA expression studies using the primers in both the 5ʹ and 3ʹ regions of the gene specific to PRRT3 ([Fig. 3A](#F3){ref-type="fig"}) revealed the highest relative expression in the pituitary, followed by muscle, pancreas, rectum, and tonsil ([Fig. 3C](#F3){ref-type="fig"}). Other tissues, including the brain, showed a low level of expression (C~t~ value ≥ 30) (Supplementary Table 1). All supplementary materials are located in a digital research materials repository \[[@CIT0017]\].

Based on the secondary structure prediction of the human PRRT3 long form, we show the possible protein insertion in the membrane ([Fig. 3D](#F3){ref-type="fig"}) with the amino-terminus being intracellular while the carboxy-terminus is extracellular. The variant p.E394K is in the coiled-coil region of the long isoform, near the cell membrane, but does not affect the short isoform ([Fig. 3E](#F3){ref-type="fig"}).

Discussion {#s8}
==========

Given the strong conservation of PRRT3 to other proteins of the PRRT family, some functional clues can be derived. Just like PRRT2, PRRT3 could also be involved in exocytosis, transporting intracellular molecules to the cell exterior on demand \[[@CIT0018], [@CIT0019]\]. Preliminary observations showing colocalization of Prrt3 and synaptophysin \[[@CIT0020]\] support its role in vesicle exocytosis in pituitary cells as well as in neurons \[[@CIT0021]\]. Preliminary phenotyping of the homozygous *Prrt3* knockout mice, with deletion of the entire *Prrt3* affecting the expression of both the isoforms, revealed small size and high mortality before 7 days of age \[[@CIT0022]\]. These observations suggest a critical role of PRRT3 in neurobiology and in sustaining life after birth. However, our patients, with a unique *PRRT3* homozygous missense variant, which likely affects the function of the long isoform partially, had milder phenotype than the knockout mice.

Our patients had several unique clinical features suggestive of progeroid syndrome, including short stature, microcephaly, mandibular hypoplasia, pointed nose, shrill voice, severe osteoporosis, and loss of hair from the eyebrows. According to Biller et al \[[@CIT0023]\], a baseline serum IGF-1 level \< 2 SD score, or \< 77 ng/mL has a 100% specificity and 46% sensitivity for diagnosis of GH deficiency. In both our patients, serum IGF-1 levels were below 3 SD score and \< 77 ng/mL, thus diagnostic of GH deficiency. Low serum IGF-1 levels in our patients are unlikely to be due to malnutrition as there was no evidence of malnutrition in the affected patients who had normal levels of serum protein, albumin, and lipids. The low BMIs in our patients were part of the novel autosomal recessive syndrome. Furthermore, both the patients had low serum GH response on glucagon stimulation test, especially considering that they received a fixed dose of 1 mg of glucagon despite their low body weights of 31 kg and 29.3 kg, suggesting mild GH deficiency \[[@CIT0024], [@CIT0025]\]. The expression of *PRRT3* messenger RNA is also observed in the mouse inner ear hair cells \[[@CIT0026]\] and may explain high-frequency hearing loss in the proband. However, patient J100.5 did not have hearing loss. Both the patients had vitamin D deficiency and secondary hyperparathyroidism, which, along with mild GH deficiency, may be contributing to osteoporosis and short stature. Interestingly, despite mild GH deficiency, the bone age was not delayed in either of the affected participants.

Each of the previously reported progeroid syndromes displays only a subset of the features of normal aging \[[@CIT0027]\]. In many patients, accelerated aging, driven by genetic variants, begins early in childhood, resulting in profound growth retardation and poor sexual development. The sexual development of our patients appears near normal, but the male had no facial hair and the female had irregular menstrual cycles. Both of them had normal serum gonadotropin levels, and the male had normal testosterone and the female had normal estradiol levels. The reproductive capabilities of our patients are not known. Although physical examination suggested scant subcutaneous fat in the extremities of both our patients, the objective evaluation of regional body fat by DEXA scans and whole-body MRI did not support a lipodystrophic phenotype.

One limitation of the current study is that there is only 1 nuclear family available. Moreover, the function of PRRT3 is largely unknown, and there is no human disorder reported to be associated with it yet. As such, the p.Glu394Lys variant is only classified as of uncertain significance by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology guidelines \[[@CIT0031]\]. It meets the criterion of absence in population databases, but the in silico predictions are conflicting. It is well conserved (genomic evolutionary rate profiling++ = 4.89), predicted to be probably damaging by some algorithms (combined annotation-dependent depletion score = 25.2; PolyPhen = 0.994) but likely benign by other algorithms (scale-invariant feature transform = 0.071; rare exome variant ensemble learner = 0.095). However, its cosegregation with phenotype constitutes a moderate evidence of being pathogenic. The genotype-phenotype cosegregation probability proposed by Jarvik and Browning \[[@CIT0032]\] can be calculated as $N = \left( 1/4 \right) \times \left( 3/4 \right)^{5}\,{and}\,{is} < 1/16$, where the first and second factors correspond to the affected and unaffected participants, respectively. Based on the Clinical Genome Resource classification method \[[@CIT0033]\], the strength of evidence is "limited" with approximately 2 points from the genetic evidence. Identification of a second family with similar phenotype caused by biallelic variants in *PRRT3* would confirm our discovery and shed more light on the function of the gene. We have made a submission (ID:50378) to GeneMatcher \[[@CIT0034]\], but so far have not found any other pedigree with *PRRT3* biallelic variants.

Another limitation is that we only performed whole exome instead of whole genome sequencing. There is always a likelihood that the disease-causing variant lies in the noncoding regions. Moreover, there can be multiple genetic causes of underlying complex phenotypes such as progeria, particularly in a consanguineous pedigree where there are long stretches of homozygous regions in the affected participants. In the current study, we manually checked that there was no pathogenic variant in the progeroid syndrome genes \[[@CIT0015]\] in either of the affected participants, and none of the progeroid syndrome causing genes was located in a homozygous region shared by the 2 affected participants but heterozygous in the unaffected participants.

We conclude that the homozygous p.Glu394Lys variant in *PRRT3* may be associated with a novel autosomal recessive, progeroid syndrome with short stature, mandibular hypoplasia, osteoporosis, short eyebrows, and mild GH deficiency. Our report extends the spectrum of progeroid syndromes and elucidates important functions of PRRT3 in human biology including secretion of GH from the pituitary.
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